Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation-Reference-Cited by-同舟云学术

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation

Published:2011-11-28 Issue:6 Volume:13 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Wang Yen-Chao,Morrison Gladys,Gillihan Ryan,Guo Jun,Ward Robin M,Fu Xiaoyong,Botero Maria F,Healy Nuala A,Hilsenbeck Susan G,Phillips Gail Lewis,Chamness Gary C,Rimawi Mothaffar F,Osborne C Kent,Schiff Rachel

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr3067.pdf

Reference46 articles.

1. Bublil EM, Yarden Y: The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol. 2007, 19: 124-134. 10.1016/j.ceb.2007.02.008.

2. Citri A, Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006, 7: 505-516. 10.1038/nrm1962.

3. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2: 127-137. 10.1038/35052073.

4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182. 10.1126/science.3798106.

5. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006, 355: 2733-2743. 10.1056/NEJMoa064320.

Cited by 227 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Wise and skillful utilization of contemporary endocrine therapies for the treatment of ER+/HER2– advanced breast cancer;Oncology in Clinical Practice;2024-08-21

2. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24

3. The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer;Cancer Treatment Reviews;2024-07

4. Mutation and cell state compatibility is required and targetable in Ph+acute lymphoblastic leukemia minimal residual disease;2024-06-10

5. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer;Medicina;2024-06-07